Answers are grounded in this paper and cite their sources.
Despite a large need for new hypoglycemic therapies, given the epidemic of type 2 diabetes, very few agents have been introduced during the past 20 years. The thiazolidinediones represent a potentially important new group of drugs with a mechanism of action differing from and perhaps complementary to that of existing therapies. This article discusses present data on mechanisms, indications, and limitations of thiazolidinedione therapy.
No takes yet. Share an insight, caveat, or question.
Hannele Yki‐Järvinen (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: